Cargando…

Isoschaftoside Reverses Nonalcoholic Fatty Liver Disease via Activating Autophagy In Vivo and In Vitro

Nonalcoholic fatty liver disease (NAFLD) is the most common metabolic liver disease globally, and the incidence of NAFLD has been increasing rapidly year by year. Currently, there is no effective pharmacotherapy for NAFLD. Therefore, studies are urgently needed to explore therapeutic drugs for NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yanze, Kang, Yixing, Yi, Jing, Lin, Qirui, Zhang, Chaochuang, Lin, Zewei, Yan, Zilong, Qu, Jianhua, Liu, Jikui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252632/ https://www.ncbi.nlm.nih.gov/pubmed/35795282 http://dx.doi.org/10.1155/2022/2122563

Ejemplares similares

NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis
por: Yan, Zilong, et al.
Publicado: (2021)

Inhibition of NEK7 Suppressed Hepatocellular Carcinoma Progression by Mediating Cancer Cell Pyroptosis
por: Yan, Zilong, et al.
Publicado: (2022)

Isoschaftoside Inhibits Lipopolysaccharide-Induced Inflammation in Microglia through Regulation of HIF-1α-Mediated Metabolic Reprogramming
por: Guan, Shuyuan, et al.
Publicado: (2022)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao, Yuqing, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease Progression in Rats is Accelerated by Splenic Regulation of Liver PTEN/AKT
por: Wang, Ziming, et al.
Publicado: (2015)

Silibinin improves nonalcoholic fatty liver by regulating the expression of miR-122: An in vitro and in vivo study
por: Yang, Liying, et al.
Publicado: (2021)

lncRNA DQ786243 promotes hepatocellular carcinoma cell invasion and proliferation by regulating the miR-15b-5p/Wnt3A axis
por: Lin, Zewei, et al.
Publicado: (2022)

The interplay of microRNAs and transcription factors in autophagy regulation in nonalcoholic fatty liver disease
por: Kim, Yumi, et al.
Publicado: (2021)

Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy
por: Jang, Hyun-Jun, et al.
Publicado: (2023)

Vegetarian diet, food substitution, and nonalcoholic fatty liver
por: Chiu, Tina H., et al.
Publicado: (2018)

Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
por: Oh, Yun Hwan, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease
por: Fang, Zhiqiang, et al.
Publicado: (2021)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice
por: Sakane, Sadatsugu, et al.
Publicado: (2021)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
por: Huang, Yue Ye, et al.
Publicado: (2013)

Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese
por: Huang, Xiaolin, et al.
Publicado: (2015)

Coffeeberry Activates the CaMKII/CREB/BDNF Pathway, Normalizes Autophagy and Apoptosis Signaling in Nonalcoholic Fatty Liver Rodent Model
por: Lu, Meng-Chun, et al.
Publicado: (2021)

The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease
por: Zhang, Shujun, et al.
Publicado: (2017)

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
por: Donati, Benedetta, et al.
Publicado: (2017)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk
por: Du, Tingting, et al.
Publicado: (2015)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect
por: Hur, Jang Ho, et al.
Publicado: (2016)

Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer
por: Chen, Erbao, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease
por: Liu, Lu, et al.
Publicado: (2023)

Role of bioactive fatty acids in nonalcoholic fatty liver disease
por: Juárez-Hernández, Eva, et al.
Publicado: (2016)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rve048ik7v02i45khqlj3aqnr2